84 related articles for article (PubMed ID: 35115586)
1. ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis.
Gong K; Huang Y; Zheng Y; Hao W; Shi K
J Transl Med; 2024 Feb; 22(1):192. PubMed ID: 38383406
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Molnár S; Beke L; Méhes G; Póka R
Pathol Oncol Res; 2020 Oct; 26(4):2549-2555. PubMed ID: 32594311
[TBL] [Abstract][Full Text] [Related]
3. Decitabine reactivated pathways in platinum resistant ovarian cancer.
Fang F; Zuo Q; Pilrose J; Wang Y; Shen C; Li M; Wulfridge P; Matei D; Nephew KP
Oncotarget; 2014 Jun; 5(11):3579-89. PubMed ID: 25003579
[TBL] [Abstract][Full Text] [Related]
4. Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
Poon C; Duan X; Chan C; Han W; Lin W
Mol Pharm; 2016 Nov; 13(11):3665-3675. PubMed ID: 27712076
[TBL] [Abstract][Full Text] [Related]
5. A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer.
Yan T; Ma X; Zhou K; Cao J; Tian Y; Zheng H; Tong Y; Xie S; Wang Y; Guo L; Lu R
Int J Biol Sci; 2024; 20(4):1279-1296. PubMed ID: 38385070
[No Abstract] [Full Text] [Related]
6. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.
Rizvi I; Celli JP; Evans CL; Abu-Yousif AO; Muzikansky A; Pogue BW; Finkelstein D; Hasan T
Cancer Res; 2010 Nov; 70(22):9319-28. PubMed ID: 21062986
[TBL] [Abstract][Full Text] [Related]
7. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
Duska LR; Zamarin D; Hamilton E; Oza A; Fleming G; Spira A; Yeku OO; Richardson DL; Walling J; Inokuchi K; Matusow B; Bollag G; Swisher EM
JCO Precis Oncol; 2023 Sep; 7():e2300235. PubMed ID: 37797273
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract][Full Text] [Related]
9. AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming.
Chang LL; Lu PH; Yang W; Hu Y; Zheng L; Zhao Q; Lin NM; Zhang WZ
Transl Oncol; 2022 Jun; 20():101421. PubMed ID: 35429904
[TBL] [Abstract][Full Text] [Related]
10.
Gao C; Chang L; Xu T; Li X; Chen Z
J Gastrointest Oncol; 2023 Jun; 14(3):1412-1433. PubMed ID: 37435231
[TBL] [Abstract][Full Text] [Related]
11. Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer.
Fu Z; Li S; Liu J; Zhang C; Jian C; Wang L; Zhang Y; Shi C
Front Pharmacol; 2022; 13():847906. PubMed ID: 35370661
[TBL] [Abstract][Full Text] [Related]
12. LINC00540 promotes sorafenib resistance and functions as a ceRNA for miR-4677-3p to regulate AKR1C2 in hepatocellular carcinoma.
Xu K; Wang X; Hu S; Tang J; Liu S; Chen H; Zhang X; Dai P
Heliyon; 2024 Mar; 10(5):e27322. PubMed ID: 38463802
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
14. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
[TBL] [Abstract][Full Text] [Related]
15. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
16. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
17. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
[TBL] [Abstract][Full Text] [Related]
18. AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.
Badmann S; Mayr D; Schmoeckel E; Hester A; Buschmann C; Beyer S; Kolben T; Kraus F; Chelariu-Raicu A; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Sci Rep; 2022 Feb; 12(1):1862. PubMed ID: 35115586
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
